Ventilated patients, cerebral haemorrhage, GCS ≤8 |
Ampicillin-sulbactam 3-day course - 19 patients |
Noplacebo -19 patients |
Early VAP |
Weak, surrogate of death/severe disability |
Antibiotic- resistantbacteria selection not Adequately investigated |
Robust, Clinicallyrelevant for thepatient/crucial forthe health-careorganization |
21.1 (8.5 to 43.3) |
57.9 (36.3 to 76.9) |
–36.8 |
0.36 (0.14 to 0.94) |
Ventilated patients, cerebral haemorrhage, GCS ≤12 |
2-dosecefuroxime - 50patients |
Noplacebo - 50 patients |
Early VAP |
Weak, surrogate of death/severe disability |
Antibiotic- resistantbacteria selection not investigated |
Robust, Clinically relevant for the patient/crucial for the health-care organization |
16 (8.3 to 28.5) |
36 (24.1 to 49.9) |
–20 (–35.8 to −2.8) |
0.44 (0.21 to 0.93) |